CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −370 | $230.87 | $85K | 44,382 |
| 2026-05-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −780 | $232.04 | $181K | 43,602 |
| 2026-05-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −1,420 | $232.92 | $331K | 42,182 |
| 2026-05-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −800 | $234.02 | $187K | 41,382 |
| 2026-05-01 | Reardon Andrew CLO & Secretary | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,000 | 44,444 | ||
| 2026-04-01 | KOZARICH JOHN W Director | Sale 10b5-1 | −146 | $199.97 | $29K | 42,574 |
| 2026-04-01 | KOZARICH JOHN W Director | Sale 10b5-1 | −40 | $201.24 | $8K | 42,534 |
| 2026-04-01 | KOZARICH JOHN W Director | Sale 10b5-1 | −79 | $202.42 | $16K | 42,455 |
| 2026-04-01 | KOZARICH JOHN W Director | Sale 10b5-1 | −43 | $202.91 | $9K | 42,412 |
| 2026-04-01 | KOZARICH JOHN W Director | Sale 10b5-1 | −159 | $204.26 | $32K | 42,253 |
| 2026-04-01 | Reardon Andrew CLO & Secretary | Option exercise 10b5-1 | +5,000 | $52.27 | $261K | 46,382 |
| 2026-04-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −460 | $198.85 | $91K | 45,922 |
| 2026-04-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −1,302 | $199.72 | $260K | 44,620 |
| 2026-04-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −1,238 | $200.94 | $249K | 43,382 |
| 2026-04-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −700 | $201.90 | $141K | 42,682 |
| 2026-04-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −963 | $203.22 | $196K | 41,719 |
| 2026-04-01 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −337 | $204.50 | $69K | 41,382 |
| 2026-04-01 | Reardon Andrew CLO & Secretary | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,000 | 49,444 | ||
| 2026-03-23 | Sabba Stephen L Director | Sale | −1,000 | $207.87 | $208K | 32,793 |
| 2026-03-11 | Espinoza Octavio Chief Financial Officer | Option exercise 10b5-1 | +2,405 | $92.65 | $223K | 24,067 |
Page 8 of 43 · 858 trades